Beaufort Securities Reiterates “Speculative Buy” Rating for N4 Pharma (N4P)
N4 Pharma (LON:N4P)‘s stock had its “speculative buy” rating reaffirmed by stock analysts at Beaufort Securities in a research note issued to investors on Thursday. They currently have a GBX 12 ($0.16) price objective on the stock. Beaufort Securities’ price objective suggests a potential upside of 47.69% from the stock’s previous close.
Shares of N4 Pharma (N4P) traded down GBX 0.38 ($0.01) on Thursday, reaching GBX 8.13 ($0.11). The company’s stock had a trading volume of 178,229 shares, compared to its average volume of 472,089. N4 Pharma has a 12 month low of GBX 4.88 ($0.07) and a 12 month high of GBX 12.50 ($0.17).
In other news, insider Nigel Theobald purchased 56,656 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of GBX 8 ($0.11) per share, with a total value of £4,532.48 ($6,070.01).
About N4 Pharma
N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.
Receive News & Ratings for N4 Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.